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migration and invasion via mechanisms
independent of the epithelial-mesenchymal
transition
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Abstract
Background: WNT5A (-/-) mammary tissue has been shown to exhibit increased ductal elongation, suggesting
elevated mammary cell migration. Increased epithelial cell migration/invasion has often but not always been linked to
the epithelial-mesenchymal transition (EMT). In the current study, we investigated the loss of WNT5A in HB2 human
mammary epithelial cells and hypothesized that this loss increased their invasion via the EMT. Based on these results,
we postulated that suppression of breast cancer cell migration and invasion by WNT5A is due to EMT reversal.
Methods: WNT5A was transiently knocked down using specific siRNAs, whereas WNT5A signaling was induced
in MDA-MB468 and MDA-MB231 breast cancer cells by stably transfecting cells with WNT5A or treating them
with recombinant WNT5A (rWNT5A). Changes in EMT markers, CD44, pAKT and AKT expression were assessed
using Western blotting and immunofluorescence. The physiological relevance of altered WNT5A signaling was
assessed using migration and invasion assays.
Results: WNT5A knockdown in HB2 mammary epithelial cells resulted in EMT-like changes and increased invasiveness,
and these changes were partially reversed by the addition of rWNT5A. These data suggest that WNT5A might inhibit
breast cancer cell migration and invasion by a similar EMT reversal. Contrary to our expectations, we did not observe
any changes in the EMT status of breast cancer cells, either after treatment with rWNT5A or stable transfection with a
WNT5A plasmid, despite the parallel WNT5A-induced inhibition of migration and invasion. Instead, we found that
WNT5A signaling impaired CD44 expression and its downstream signaling via AKT. Moreover, knocking down CD44 in
breast cancer cells using siRNA impaired cell migration and invasion.
Conclusions: WNT5A bi-directionally regulates EMT in mammary epithelial cells, thereby affecting their migration and
invasion. However, the ability of WNT5A to inhibit breast cancer cell migration and invasion is an EMT-independent
mechanism that, at least in part, can be explained by decreased CD44 expression.
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Background
The Wnt family of proteins includes secreted lipid-
modified glycoproteins that regulate diverse cellular pro-
cesses, such as proliferation, differentiation, apoptosis
and migration [1, 2]. To date, 19 members of the Wnt
gene family have been identified and placed into three
different classes based on their transforming potential [3].
WNT5A belongs to the non-transforming class and elicits
non-canonical (β-catenin-independent) signaling upon
binding to different receptors or co-receptor complexes
(Frizzled, RYK, ROR1/2, LRP5/6 and CD146) [4, 5].
WNT5A signaling has been shown to be essential for
normal development [6]. In the context of mammary
gland development, WNT5A signaling plays an import-
ant role in ductal branching, and its loss can induce in-
creased ductal extensions and larger terminal buds [7].
These findings suggest that WNT5A functions to limit
mammary epithelial cell migration during development.
The loss of WNT5A signaling plays an important role
in breast cancer progression, thereby making WNT5A a
tumor suppressor. Moreover, the loss of WNT5A
protein in breast cancer patients has been associated
with poor prognosis, early recurrence and reduced over-
all survival [8–11]. Using immunohistochemical (IHC)
staining, Borcherding et al. reported strong WNT5A
expression in normal mammary ducts and acini, but
reduced WNT5A expression was observed in 75 % of
triple negative breast cancers (TNBC), an aggressive
breast cancer subtype [12]. Accordingly, a recent study
by Zhong et al. demonstrated a loss of WNT5A in 60 %
of TNBC patients, and this loss positively correlated
with lymph node metastasis and poor recurrence-free
survival (RFS) [13]. Additionally, we have also demon-
strated that WNT5A expression can be used as a poten-
tial prognostic biomarker in pre-menopausal patients
with ER+ breast tumors [14]. Other studies of breast
cancer cells involving the treatment of cells with either
recombinant WNT5A (rWNT5A) or the stable trans-
fection of WNT5A protein demonstrated that breast
cancer cell adhesion increased, whereas their migra-
tion decreased [15–17].
A key biological event responsible for tumor cell inva-
sion and metastasis is the epithelial-mesenchymal transi-
tion (EMT). Cancer cells undergoing EMT show a loss
of cell-cell contact and polarity and acquire migratory
and invasive properties [18, 19]. Recent studies have
highlighted the importance of WNT5A in the regulation
of the EMT. In colon cancer, where WNT5A acts as a
tumor suppressor, WNT5A restoration has been shown
to inhibit EMT by antagonizing the Wnt/β-catenin sig-
naling pathway [20]. In a similar study, Cai et al. demon-
strated that microRNA-374a directly suppresses multiple
negative regulators of Wnt/β-catenin signaling, including
WNT5A, and this suppression induces EMT in breast
cancer [21]. These studies also suggest that canonical
Wnt/β-catenin signaling plays a parallel role as a poten-
tial regulator of EMT in these cancers. In contrast,
WNT5A has been shown to positively drive EMT-like
changes in gastric cancer, pancreatic cancer, ovarian can-
cer and malignant melanomas, where WNT5A acts as a
tumor promoter [22–26].
The aim of the present study was to clarify whether
the loss of WNT5A expression can induce an EMT
phenotype to consequently increase the invasiveness of
breast epithelial cells. Moreover, this study aimed to de-
termine whether inhibition of such a mechanism could
explain our previous observation that WNT5A can sup-
press the invasion of breast cancer cells. In the present
study, we employed HB2 human mammary epithelial
cells (which endogenously express WNT5A) as a model
system to elucidate the early events associated with the
loss of WNT5A protein and EMT changes. However, we
also examined whether WNT5A inhibits breast cancer




The human mammary epithelial cell line HB2, which is
a subclone of the MTSV1-7 cell line, was kindly
provided by the laboratory of Dr. J. Taylor Papadimitriou
(ICRF, UK). HB2 cells are a suitable model to study
mammary cell responses because they endogenously ex-
press WNT5A protein (mimicking the clinical situation;
normal mammary epithelial cells and acini endogen-
ously express WNT5A protein). Thus, the modulation
of WNT5A expression can be directly investigated via
phenotypic changes and changes in the expression of bio-
markers/molecules of interest in these cells. The human
mammary carcinoma cell lines MDA-MB468 (Lot No.
60880170) and MDA-MB231 (Lot No. 61093072) were
procured directly from the American Type Culture
Collection (ATCC). All cell lines were grown in DMEM
(Hyclone, UT, USA) supplemented with 10 % FBS, 5 U/ml
penicillin, 0.5 U/ml streptomycin, and 2 mM glutamine.
The growth media for HB2 cells was also supplemented
with 10 μg/ml bovine insulin and 5 μg/ml hydrocortisone.
The cell lines were frequently screened for mycoplasma
contamination using an EZ-PCR kit (HaEmek, Israel).
siRNA transfections
Sequence-specific siRNAs were used to transiently
knock down WNT5A, E-cadherin and CD44. We pur-
chased Silencer® select pre-designed siRNAs for WNT5A
[ID: s14871 (siRNA 1) and ID: s14872 (siRNA 2)], E-
cadherin (ID: 146381) and negative control #1 siRNA
from Applied Biosystems (CA, USA). SMARTpool CD44
siRNA (h) (Cat. no. sc-29342) was procured from Santa
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Cruz Biotechnology, Inc. (TX, USA). Briefly, cells were
transiently transfected with a transfection complex con-
sisting of 50 or 100 nM siRNA (final concentration) and
Lipofectamine 2000 transfection reagent (Invitrogen,
CA, USA) suspended in serum-free DMEM. After 6 h,
the transfection complex was removed, and the cells
were replenished with fresh DMEM containing 10 %
FBS. The cells were then allowed to grow for the next
48 h prior to being used for Western blotting, immuno-
fluorescence staining, or an invasion assay.
Western blotting
Untreated cells or cells treated with siRNAs, rWNT5A, or
U0126 were washed with ice-cold PBS and lysed in ice-
cold phosphorylation lysis buffer (PLB). The estimation of
protein concentration, SDS-PAGE and visualization proce-
dures were performed as described in Prasad et al. [16].
The following primary antibodies were used: anti-WNT5A
from R & D Systems (MN, USA); anti-E-cadherin, anti-
pAKT (ser473), anti-total AKT, anti-vimentin, anti-N-
cadherin, anti-Slug and anti-pERK1/2 from Cell Signaling
Technology (MA, USA); anti-α-tubulin antibodies from
Santa Cruz Biotechnology, Inc. (TX, USA); and anti-CD44
(156-3C11) antibody from Thermo Scientific (CA, USA).
The secondary antibodies used in this study were goat
anti-mouse, goat anti-rabbit and rabbit anti-goat, which
were procured from Dako (Glostrup, Denmark).
Phase-contrast and confocal microscopy
For phase-contrast microscopy, HB2 cells were grown in
6-well culture plates or on glass coverslips and treated
with either WNT5A siRNA or E-cadherin siRNA. For
the negative control, cells were treated with scrambled
siRNA. After 48 h, the HB2 cells were photographed
(using a Nikon model TMS-F microscope) and analyzed
with NIS-Elements software (Tokyo, Japan).
For confocal microscopy, the cells were grown on 13-
mm glass coverslips for 24 h at 37 °C in a humidified
incubator under 5 % CO2. For the rWNT5A rescue ex-
periments, cells were transfected with WNT5A siRNA
transfection for 48 h and subsequently treated with
rWNT5A (0.4 μg/ml) for another 24 h. For CD44 immu-
nostaining of breast cancer cells stably expressing WNT5A
protein (MDA-MB468-5A and MDA-MB231-5A), the cells
were allowed to grow on 13-mm glass coverslips for 48 h
at 37 °C in a humidified incubator under 5 % CO2 in re-
duced serum conditions. After the treatments, the cells
were washed with PBS, fixed with 4 % paraformaldehyde
for 20 min and permeabilized using 0.1 % Triton X-100 for
3 min (all steps were performed at RT). Subsequently, the
cells were washed with PBS and incubated with the appro-
priate primary antibody (i.e., E-cadherin, vimentin or
CD44) in a humidified chamber at 4 °C. After an overnight
incubation, the cells were washed and incubated with the
appropriate secondary antibody (either goat anti-mouse or
goat anti-rabbit Alexa 488) (Molecular Probes™, Oregon,
USA) for 45 min at room temperature. After extensive
washing, the cells were counterstained with DAPI (300 nM
in PBS) for 2 min. Next, the coverslips were mounted on
glass slides with Dako fluorescent mounting medium and
viewed with a Carl Zeiss LSM 700 (Oberkochen, Germany)
confocal microscope. Immunofluorescence staining was
semi-quantitatively assessed using ImageJ software (NIH,
MD, USA). Briefly, the images were first processed using
the process tool to sharpen the images, and plot profiles
were generated utilizing a line cross-sectioning approach
for each cell. The areas inside the peaks depicting mem-
branous or cytoplasmic intensities were evaluated using
the freehand selection and measurement tools. The result-
ant graphs reveal the mean fluorescence (a.u.) correspond-
ing to the membranous or cytoplasmic staining of the
protein in each cell.
Transwell invasion and migration assays
WNT5A, E-cadherin or CD44 siRNA-transfected cells
were washed and detached with Versene (Gibco®, NY,
USA) and subsequently re-suspended as single-cell sus-
pensions in low-serum DMEM (supplemented with 1 %
FBS). The cell invasion assays were carried out in BD
Matrigel™ invasion chambers (MA, USA), and the cells
were counted using an automated cell counter (Countess™,
Invitrogen, Korea). A total of 50,000 cells in low-serum
DMEM were added to the upper chamber [for rWNT5A
treatment, rWNT5A (0.4 μg/ml) was freshly added to the
medium], and the lower chamber was filled with 0.7 ml of
DMEM supplemented with 10 % FBS. The cells were
allowed to invade for 24 h at 37 °C in a humidified incuba-
tor containing 5 % CO2. After incubation, the cells in the
insert were fixed with 4 % paraformaldehyde for 10 min at
RT. The non-invading cells on the upper side of the insert
were removed with a cotton-tipped applicator and further
processed as described by Linnskog et al. [27]. Transwell
migration assays for CD44 siRNA-treated breast cancer
cells were performed in a similar manner using a cell cul-
ture insert containing a PET membrane with an 8.0 μm
pore size (Ref# 353097; Corning Incorporated, NY, USA).
Wound healing assay
The migration of MDA-MB468 and MDA-MB231 cells
was analyzed using a wound-healing assay. A total of 2 ×
105 cells/well were seeded in 12-well tissue culture plates
and grown either in the presence of rWNT5A (0.4 μg/ml)
or the vehicle control suspended in low-serum DMEM
(supplemented with 1 % FBS) for 48 h. The rWNT5A was
replenished every 24 h. Wounds were then created by
scratching the monolayer, and the cells were subse-
quently allowed to migrate for 24 h under the same
media conditions. The wounds were photographed at
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10X magnification with a Nikon microscope (Model:
TMS-F) immediately after wounding and 72 h after
wounding. The images were compared and analyzed
with ImageJ software (NIH, MD, USA).
BrdU incorporation assay
The proliferation of MDA-MB468 and MDA-MB231
cells was examined for 72 h using an ELISA BrdU kit from
Roche Diagnostics GmbH (Mannheim, Germany). Briefly,
1 × 104 cells/well were seeded in a 96-well ELISA plate
and treated for 72 h with either rWNT5A (0.4 μg/ml) or
the vehicle control suspended in low serum DMEM (sup-
plemented with 1 % FBS). The rWNT5A was replenished
every 24 h. During the final 24 h, 10 μM BrdU was added
to the cells. After the termination of the experiment, the
cells were fixed with FixDenat for 30 min and incubated
with anti-BrdU-POD for 90 min. Antibody binding was
detected via the addition of a specific substrate, and the
resultant absorbance was recorded according to the man-
ufacturer’s instructions.
Statistical analysis
All the data presented herein are expressed as the mean
± standard error of the mean. Each experiment was
repeated at least three times unless otherwise stated. A
statistical analysis was performed using Student’s t-test,
and p values <0.05 were considered significant. All stat-
istical tests and graphs were generated using GraphPad
Prism 5.0 software (CA, USA).
Results
siRNA-mediated knockdown of WNT5A induces “EMT-like”
changes in human mammary epithelial HB2 cells
The experiments in this study were conducted because
the levels of WNT5A protein were previously shown to
be higher in the pre-neoplastic mammary gland and
early tumors than in late-stage tumors [12]. Thus, we
hypothesized that the loss of WNT5A in non-cancerous
breast cells is associated with changes in the EMT status
of cells. To investigate this hypothesis, we used human
mammary epithelial HB2 cells in this study [28] because
they are non-cancerous and endogenously express WNT5A
protein. Recently, Nash et al. advocated the use of luminal
HB2 over basal MCF-10A cells for a 3D multi-cellular in
vitro model of normal human breast tissue because the
morphology attained by HB2 cells in tri-culture was similar
to that of normal human breast acini [29]. In addition, two
breast cancer cell lines, MDA-MB468 and MDA-MB231
cells, were examined in this study.
In initial experiments, endogenous WNT5A expression
was evaluated in all three breast cell lines via a Western
blot analysis (Fig. 1a). WNT5A protein expression was
not detectable in either breast cancer cell line (MDA-
MB468 and MDA-MB231) compared to HB2 cells, which
endogenously express WNT5A protein (Fig. 1a). Next,
HB2 cells were transiently transfected with two different
sequence-specific siRNAs targeting WNT5A (as described
in the Methods section) for 48 h, and Western blotting
was performed using whole cell lysates to analyze the
changes in WNT5A protein expression. The Western blot
data demonstrated that transfection with siRNAs targeting
WNT5A mRNA significantly decreased the levels of
WNT5A protein (Fig. 1b). Moreover, a morphological
evaluation of WNT5A siRNA-treated HB2 cells re-
vealed distinct phenotypic changes, such as the loss of
cell-cell adhesion, fibroblast-like morphology and cellu-
lar scattering (Fig. 1c). These results further prompted
us to investigate the changes in EMT markers in
WNT5A siRNA-treated HB2 cells. Specifically, trans-
fection with two different sequence-specific WNT5A
siRNAs resulted in the deregulation of various EMT
markers in HB2 cells (Fig. 2a). Integrated densitometric
values (IDVs) revealed a significant decrease in the ex-
pression of the epithelial marker E-cadherin (Fig. 2b)
and an increase in the expression of the mesenchymal
marker vimentin (Fig. 2c) in WNT5A siRNA-treated
HB2 cells compared with controls. However, the levels
of β-catenin did not change (Fig. 2d). Overall, our re-
sults clearly demonstrate that WNT5A is integral to
the maintenance of epithelial architecture in mammary
epithelial HB2 cells. Subsequent experiments employed
only WNT5A siRNA 2 because the results from the
knockdown showed that this siRNA produces more con-
sistent and reproducible results than WNT5A siRNA 1.
Addition of rWNT5A rescues the “EMT-like” changes
induced by WNT5A knockdown in HB2 cells
In the next set of experiments, we investigated the abil-
ity of ectopic WNT5A to reverse the “EMT-like” charac-
teristics of HB2 cells transfected with WNT5A siRNA.
For these experiments, we used recombinant WNT5A
(rWNT5A) (R&D Systems, MN, USA). HB2 cells that
had been transiently transfected with WNT5A siRNA 2
for 48 h were treated with rWNT5A (0.4 μg/ml dose)
for 24 h. In the control experiments, vehicle (0.1 mM
EDTA, 0.5 % CHAPS, and 0.5 % BSA dissolved in PBS)
was used instead of rWNT5A. An immunofluorescence
analysis revealed that membranous E-cadherin expression
was drastically decreased in HB2 cells treated with
WNT5A siRNA and partially restored after rWNT5A
addition (Fig. 3a panel: E-cadherin). In agreement with
this observation, we also observed an increase in the mes-
enchymal protein vimentin in WNT5A siRNA-treated
HB2 cells; this effect was subsequently reduced by
rWNT5A (Fig. 3a panel: vimentin). The immunofluores-
cence data were further validated by semi-quantitatively
estimating the fluorescence intensities of membranous E-
cadherin and vimentin in rWNT5A-treated and untreated
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HB2 cells (Additional file 1a and b). Similar to the im-
munofluorescence data, Western blotting of the whole cell
lysate also revealed an increase in E-cadherin expression
and a decrease in vimentin expression after the rWNT5A
treatment of siRNA-transfected HB2 cells (Fig. 3b). The
treatment of WNT5A siRNA HB2 cells with rWNT5A
also significantly decreased the expression of other mesen-
chymal markers (i.e., N-cadherin and Slug) compared to
their increased expression in WNT5A siRNA-treated HB2
cells (Additional file 1c, d and e). As previously observed,
we did not find any changes in the β-catenin expression
profile in rWNT5A-treated and untreated WNT5A
siRNA-transfected HB2 cells (data not shown).
To assess the effect the above-described changes in
EMT markers on HB2 cell physiology, we conducted in-
vasion assays (as described in the Methods section). We
observed that WNT5A-depleted HB2 cells (transfected
with WNT5A siRNA) were more invasive (p = 0.011)
than scrambled control-treated cells, suggesting that the
EMT changes associated with a loss of WNT5A in HB2
cells were coupled with increased invasion (Fig. 3c).
Furthermore, we also observed that the exogenous
supplementation of rWNT5A significantly inhibited this
increased invasion (p = 0.035) (Fig. 3c). These data cor-
roborate the changes in EMT marker profiles and sug-
gest that the loss of WNT5A triggers mammary cells to
acquire a more invasive and mesenchymal phenotype.
As a proof-of-concept, we specifically knocked down
the expression of E-cadherin in HB2 cells to demonstrate
that a decrease in this epithelial marker can result in the
increased invasion of HB2 cells (Additional file 2a) and
that this decrease is an important event in WNT5A
Fig. 1 The loss of WNT5A induces “EMT-like” changes in human mammary epithelial HB2 cells. a Representative Western blot showing the
presence of WNT5A protein in whole-cell lysates from MDA-MB468, HB2 and MDA-MB231 cells (n= 3). MDA-MB468 cells that were stably transfected with
the WNT5A plasmid (MDA-MB468-5A) were used as a positive control for the experiment. Tubulin was used as a loading control. b Two different anti-
WNT5A siRNA oligonucleotides were tested on HB2 cells. Total cell lysates were prepared 48 h after transfection, and Western blotting for the WNT5A
protein was performed (as described in the Methods section). Error bars represent the standard error of the mean (n= 4). *p < 0.05. c Phase-contrast
microscopy showing morphological changes in HB2 cells grown on glass coverslips and transfected with WNT5A siRNA for 48 h. The
magnification used was 20X
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siRNA-treated HB2 cells. Our results also showed that the
effect of treating HB2 cells with E-cadherin siRNA on
morphology is similar to that of WNT5A siRNA treat-
ment (Additional file 2b). Moreover, further analysis re-
vealed that the loss of E-cadherin alone cannot regulate
the expression of the vimentin and WNT5A proteins in
HB2 cells (Additional file 2c).
Overall, these data suggest that the loss of WNT5A stim-
ulates mammary epithelial HB2 cells towards EMT and in-
creased invasion; however, the subsequent restoration of
WNT5A resulted in EMT reversal and impaired invasion.
WNT5A-treated breast cancer cells exhibit no change in
EMT markers
In the current study, we found that WNT5A loss in hu-
man mammary epithelial HB2 cells induced EMTand that
ectopic WNT5A treatment can reverse the EMT process.
These results prompted us to speculate that a similar
EMT reversal mediates the ability of WNT5A signaling to
impair breast cancer cell migration and invasion. To in-
vestigate this possibility, we used the MDA-MB468 and
MDA-MB231 metastatic breast cancer cell lines. Because
both cell lines lack endogenous WNT5A expression, the
cells were stimulated with rWNT5A (0.4 μg/ml) for 24, 48
and 72 h, and total protein was then extracted from the
cells for Western blotting (as described in the Methods
section). In MDA-MB468 cells, the Western blot analysis
revealed no changes in the protein expression of any EMT
marker (E-cadherin, vimentin or β-catenin) relative to the
vehicle-treated control when the cells were treated with
rWNT5A for 72 h (Fig. 4a). MDA-MB468 cells did not
express vimentin protein. We further validated these re-
sults with an RT-qPCR analysis for these EMT markers at
24, 48 and 72 h and did not find changes in any analyzed
Fig. 2 The loss of WNT5A in HB2 cells induces changes in EMT markers. a Representative Western blots showing changes in EMT markers upon
the treatment of HB2 cells with WNT5A siRNAs. Two sequence-specific siRNAs targeted against WNT5A were used in the present experiment (as
described in the Methods section). The EMT markers b E-cadherin, c vimentin and d β-catenin were quantified by calculating the integrated
densitometric values and normalizing them to the tubulin levels. Statistical comparisons were made with Student’s t-test (b, c and d). All error
bars represent the standard error of the mean (n = 5). *p < 0.05, **p = 0.01
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transcript (data not shown). Similar results were obtained
in MDA-MB231 cells treated with rWNT5A for 72 h:
treatment with rWNT5A did not cause changes in the
protein levels (Fig. 4b) or the mRNA levels (data not
shown) of EMT markers.
Consequently, we hypothesized that long-term exposure
to WNT5A is required to induce EMT reversal in breast
cancer cells. To investigate this possibility, we analyzed the
changes in EMT marker status in MDA-MB468 and MDA
MB-231 cells stably transfected with a WNT5A plasmid
(MDA-MB468-5A and MDA-MB231-5A cells) relative to
MDA-MB468 and MDA-MB231 cells stably transfected
with an empty vector (MDA-MB468-EV; MDA-MB231-
EV). We did not observe changes in any EMT marker ana-
lyzed at the protein level (Fig. 4c and d). Notably, we
have previously demonstrated that breast cancer cells
transfected with the WNT5A plasmid exhibit low mi-
gration and invasion compared to control MDA-MB-
468-EV cells [16].
WNT5A inhibits the migration and invasion of breast
cancer cells via an EMT-independent mechanism(s)
WNT5A-treated breast cancer cells did not exhibit
changes EMT markers, which led us to hypothesize that
Fig. 3 rWNT5A partially rescues the EMT changes induced in HB2 cells. a Immunofluorescence staining for E-cadherin and vimentin was performed
for the WNT5A rescue experiments. In these experiments, HB2 cells that were transiently transfected with WNT5A siRNA were treated with rWNT5A
(0.4 μg/ml). For visualization, a secondary goat anti-mouse/-rabbit Alexa-488-labeled antibody was used together with DAPI counterstaining. The
magnification used was 60X (n = 3). b Representative Western blot demonstrating a reversal in the expression of the epithelial markers E-cadherin and
vimentin in rWNT5A-treated cells compared with cells treated with WNT5A siRNA alone. c An invasion analysis was performed using a Transwell assay, in
which WNT5A siRNA-treated cells were plated on Transwell invasion inserts in either the presence or absence of rWNT5A. Vehicle-exposed cells were used
as negative controls. Statistical comparisons were made with Student’s t-test. All error bars represent the standard error of the mean (n= 4). *p< 0.05
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WNT5A suppresses the migration and invasion of
breast cancer cells via an EMT-independent mecha-
nism(s). To investigate this possibility, we performed a
72 h wound healing migration assay using MDA-MB468
and MDA-MB231 cells in the presence of rWNT5A, as
described in the Methods section. This experiment was
vital because in our previous studies, we only investi-
gated the effect of rWNT5A on cancer cell migration/in-
vasion for 24–48 h. In agreement with our earlier
studies, we found that the migration of both breast can-
cer cell lines was significantly inhibited compared with
the controls when treated with rWNT5A (0.4 μg/ml) for
72 h (Fig. 5a and c). We also performed a parallel BrdU
proliferation assay at the same time points to eliminate
the possibility that the changes in migration were due to
an indirect effect on proliferation (Additional file 3). In
the next step, the invasion potential of each breast can-
cer cell line (MDA-MB468 and MDA-MB231) was ana-
lyzed. We found a significant reduction in the invasion
of both breast cancer cell lines after treatment with
rWNT5A for 72 h (Fig. 5b and d). These results fur-
ther confirmed that WNT5A inhibits the migration
and invasion of breast cancer cells without reversing
the EMT process.
WNT5A inhibits CD44-AKT signaling in breast cancer cells
Because the WNT5A-mediated inhibition of breast cancer
cell migration and invasion was independent of EMT re-
versal, we explored the involvement of alternative path-
ways that might be triggered by WNT5A to curb the
Fig. 4 The WNT5A-mediated effects on breast cancer cells were independent of EMT reversal. a Representative Western blot showing changes in
EMT markers (viz. E-cadherin, vimentin and β-catenin) in MDA-MB468 cells after exposure to rWNT5A for 24, 48 and 72 h. b Representative Western
blots showing changes in EMT markers (viz. E-cadherin, vimentin and β-catenin) in MDA-MB231 cells after exposure to rWNT5A for 24, 48 and 72 h.
c Representative Western blot showing changes in EMT markers in WNT5A-expressing MDA-MB468 cells compared with empty vector (EV)-transfected
MDA-MB468 cells. d Representative Western blot showing changes in EMT markers in WNT5A-expressing MDA-MB231 cells compared with empty
vector (EV)-transfected MDA-MB231 cells
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spread of breast cancer cells. To this end, we investigated
the effect of WNT5A on CD44, a transmembrane glyco-
protein, for several reasons. First, increased CD44 expres-
sion has been correlated with breast cancer cell metastasis
and a poor prognosis [30, 31]. Second, Jiang et al. com-
bined microarray and RNA-Seq approaches to demon-
strate that WNT5A alters the splicing of CD44 and that
the levels of specific variant isoforms of CD44 (e.g.,
CD44v4 and CD44v6) were reduced in a WNT5A-
expressing cell line [17]. In our previous studies, we also
demonstrated that the role of WNT5A in increased adhe-
sion is mediated by its ability to phosphorylate DDR1,
resulting in the reduced migration of breast cancer cells
[32, 33]. Because CD44 overexpression alone is sufficient
to induce breast cancer cell migration and invasion [34],
we investigated the ability of WNT5A signaling to directly
regulate CD44 expression in breast cancer cells. There-
fore, we next analyzed the expression of CD44 protein in
breast cancer cells stably expressing WNT5A protein.
CD44 immunofluorescence staining revealed that both
breast cancer cell lines (MDA-MB468-5A and MDA-
MB231-5A) expressed reduced levels CD44 membrane
protein compared to their counterpart controls, which
were transfected with empty vector (Additional file 4).
Subsequently, we validated our findings by Western blot-
ting, demonstrating that WNT5A expression does indeed
inhibit the expression of CD44 protein in WNT5A-ex-
pressing breast cancer cell lines (Fig. 6a and b). CD44 is a
receptor that can stimulate tumorigenic signals via a variety
of downstream pathways and effectors, such as PI3K/AKT
signaling and MMP-9. Therefore, we next investigated
whether the WNT5A-mediated reduction in CD44 de-
creased PI3K/AKT signaling in breast cancer cells. We
found a significant reduction in the expression of pAKT in
both WNT5A-transfected breast cancer cell lines (MDA-
MB468-5A and MDA-MB231-5A) compared to control
cells (Fig. 6c and d). The data were further validated in par-
ental MDA-MB231 cells treated with rWNT5A (0.2 and
Fig. 5 WNT5A significantly decreases the migration and invasion of breast cancer cells. a A wound-healing migration assay and b a Transwell invasion
assay were performed with the breast cancer cell line MDA-MB468 in either the presence or absence of rWNT5A (0.4 μg/ml) for 72 h. Vehicle-treated
MDA-MB468 cells were used as controls. Similarly, the relative migration and invasion (c and d) of the breast cancer cell line MDA-MB231 were
quantified in the presence or absence of rWNT5A (0.4 μg/ml) for 72 h. Vehicle-treated MDA-MB231 cells were used as controls. Statistical comparisons
were made with Student’s t-test (a, b, c, and d). All error bars represent the standard error of the mean (n = 4). *p < 0.05, ***p = 0.001
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Fig. 6 (See legend on next page.)
Prasad et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:144 Page 10 of 15
0.4 μg/ml) for 24 h (Additional file 5a). We observed a
dose-dependent decrease in the expression of pAKT,
thereby validating our finding that WNT5A indeed inhibits
the CD44-AKT signaling pathway in breast cancer cells.
Furthermore, to assess the effect of WNT5A on CD44
protein expression in HB2 mammary epithelial cells, we
knocked down the expression of WNT5A these cells
using siRNA (Additional file 5b). This knockdown did
not affect the level of CD44 protein, suggesting that
WNT5A does not modulate CD44 expression in HB2
mammary epithelial cells.
CD44 knockdown reduces the level of pAKT, migration
and invasion of breast cancer cell
Our experiments showed that WNT5A inhibited CD44
expression in breast cancer cells but not in HB2 cells.
Therefore, we hypothesized that reduced levels of CD44
are responsible for the WNT5A-mediated reduction in
the migration and invasion of breast cancer cells. To in-
vestigate this hypothesis, we used siRNA to knock down
CD44 expression in MDA-MB231 cells and evaluated
the effect of this knockdown on the pAKT levels, cell
migration and invasion. CD44 siRNA-treated cells dem-
onstrated reduced pAKT levels (Fig. 7a) and significant
decreases in their migratory and invasive capabilities com-
pared with their respective controls (Fig. 7b and c). In sup-
port of these findings, MDA-MB468 cells treated with
CD44 siRNA also showed a significant decrease in migra-
tion compared to control cells (Additional file 6). Overall,
our results demonstrate that the WNT5A-mediated re-
duction in CD44-AKT signaling plays an important role in
inhibiting breast cancer cell migration and invasion.
We previously demonstrated that WNT5A inhibits
ERK1/2 signaling in breast cancer cells [16]. In the present
study, we showed that WNT5A affects breast cancer cell
migration and invasion by inhibiting CD44 expression and
downstream AKT signaling. To investigate the role of al-
tered ERK1/2 signaling in the WNT5A-mediated inhibition
of CD44, we treated breast cancer cell lines with U0126 (a
selective inhibitor of MAP kinase). Treatment with U0126
for 24 h drastically reduced CD44 protein expression in
MDA-MB468 (Fig. 7d) and MDA-MB231 (Fig. 7e) cells,
suggesting that CD44 is a downstream target of the
MAP kinase pathway in these cells. Thus, these re-
sults suggest that WNT5A-impaired ERK1/2 signaling,
which as mimicked by the ERK1/2 inhibitor U0126 in
the present study, reduces CD44 expression in breast
cancer cells.
Discussion
We have previously shown that the loss of WNT5A in
HB2 cells leads to cell scattering, reduced cell-collagen
interaction and increased motility, and we established
the role of WNT5A signaling in regulating DDR1 phos-
phorylation, increased adhesion and decreased migration
[33]. In the present study, knocking down WNT5A in
mammary HB2 cells resulted in increased invasion and
EMT-like changes. These changes included phenotypic
changes, such as cellular scattering, the loss of cell-cell
adhesion and a fibroblast-like morphology, as well as
significant increases in the expression of established
mesenchymal markers. Interestingly, our data revealed
that ectopic stimulation with rWNT5A reversed the in-
creased invasion and the EMT-like changes in mammary
epithelial HB2 cells.
The above observations corroborate clinical observa-
tions made in breast cancer tissues, where a loss of
WNT5A expression has been correlated with increased
metastasis and poor outcome in breast cancer patients.
According to recent findings from Borcherding et al.,
early breast tumors and pre-neoplastic lesions express
WNT5A protein; however, its expression decreases in
late-stage tumors and lung metastases [12]. Accordingly,
Jönsson et al. have also demonstrated the loss of
WNT5A protein in invasive ductal carcinoma patients,
which is in contrast to the expression of WNT5A in
DCIS (ductal carcinoma in situ) [8]. The current litera-
ture on WNT5A expression in breast cancer strongly
advocates its role as an oncosuppressor, and the loss of
WNT5A expression is one of the causes of increased
breast cancer progression [35].
These data suggest that the ability of WNT5A signal-
ing to impair breast cancer cell migration and invasion
[16, 17] is due to an EMT reversal similar to that ob-
served in mammary HB2 cells. We previously reported
that WNT5A at least in part inhibits the migration
and invasion of breast cancer cells by reducing the
production and secretion of MMP9 [16]. This finding
is relevant to the potential of WNT5A to reverse
EMT in breast cancer cells because MMPs have been
(See figure on previous page.)
Fig. 6 WNT5A significantly inhibits CD44 and pAKT expression in breast cancer cells. a CD44 expression was analyzed in MDA-MB468-EV cells and
MDA-MB468-5A cells by Western blotting. The CD44 levels in MDA-MB468-EV and MDA-MB468-5A cells were quantified by calculating integrated density
values and normalizing them to the tubulin levels. b CD44 expression was analyzed in MDA-MB231-EV cells and MDA-MB231-5A cells by Western blotting.
CD44 levels in MDA-MB231-EV and MDA-MB231-5A cells were quantified by calculating integrated density values and normalizing them to tubulin levels.
pAKT activation was analyzed in MDA-MB468-EV cells and MDA-MB468-5A cells as in panel c and in MDA-MB231-EV cells and MDA-MB231-5A cells as in
panel d. pAKT levels were quantified by calculating integrated density values and normalizing them to total AKT levels. Statistical comparisons were made
with Student’s t-test (a, b, c and d). All error bars represent the standard error of the mean (n= 5). *p< 0.05, **p= 0.01, ***p= 0.001
Prasad et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:144 Page 11 of 15
demonstrated to facilitate EMT in these cells [36].
However, neither the rWNT5A treatment of nor stably
transfecting the WNT5A protein into breast cancer cells
produced any changes in EMT markers, although
WNT5A signaling still inhibited the migration and
invasion of both breast cancer cell lines under similar con-
ditions. Thus, WNT5A inhibits the migration and inva-
sion of breast cancer cells via an EMT-independent
mechanism. This effect of WNT5A appears to be tumor
type specific because a recent study of HCT116 colon
Fig. 7 CD44 and ERK1/2 inhibition and the migration and invasion of MDA-MB231 breast cancer cells. MDA-MB231 cells were transiently transfected
with CD44 siRNA (as described in the Methods section), and changes in the cellular characteristics were investigated. a Representative Western blot
demonstrating that the silencing of CD44 expression induces changes in pAKT levels. After CD44 knockdown, MDA-MB231 cells were subjected to
b Transwell migration and c Transwell invasion assays. Statistical comparisons were made with Student’s t-test (b and c). All error bars represent the
standard error of the mean (n = 4). *p < 0.05. d MDA-MB468 and e MDA-MB231 breast cancer cells were treated with U0126 (10 μM) or left untreated
for 24 h, and Western blotting was used to determine CD44 expression. The expression of pERK1/2 was also analyzed as an experimental control. The
blots shown are representative of three independent experiments (n = 3)
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cancer cells has suggested that WNT5A can reverse EMT
by antagonizing canonical Wnt/β-catenin signaling in
these cells [20]. Conversely, we did not find any changes
in the β-catenin expression levels in WNT5A siRNA-
treated HB2 cells or in breast cancer cell lines exposed to
WNT5A treatments. This finding further supports the
hypothesis that the function of WNT5A depends on the
cancer cell type.
EMT reversal is clearly not responsible for the
WNT5A-mediated inhibition of breast cancer cell mi-
gration and invasion; therefore, we sought alternative
explanations for this phenomenon. Our results demon-
strate that WNT5A signaling affects the expression of
the transmembrane glycoprotein CD44, and WNT5A is
known to alter the splicing of CD44 and its variant iso-
forms in breast cancer [17]. We clearly showed that
WNT5A suppresses CD44, which consequently reduces
downstream AKT signaling in breast cancer cells. CD44
is known to regulate PI3K/AKT signaling in breast can-
cer [37, 38], and this pathway plays an important role
in cell survival, invasion and metastasis [39, 40]. Con-
siderable research has indicated that MAPK-ERK
signaling regulates CD44 expression in various types of
cancer [41–44]. This finding is interesting because we
have previously demonstrated that WNT5A inhibits
ERK1/2 activity in breast cancer cells [16], which suggests
that WNT5A regulates CD44 via ERK1/2. Using an
ERK1/2 inhibitor to mimic the inhibition of ERK1/2 activ-
ity by WNT5A, we confirmed a link between ERK1/2-
MAPK signaling and CD44 expression in breast cancer
cells. In accordance with the reported positive association
between CD44 and breast cancer metastasis [45–49], the
migration and invasion of breast cancer cells significantly
impaired in our siRNA-CD44 knockdown experiments.
The experimental data presented herein corroborate the
relationship between the expression levels of WNT5A and
CD44 in clinical breast cancer samples and their relation
to disease-free survival and cumulative survival of patients
with breast cancer. Importantly, information on the inter-
action between WNT5A and CD44 cannot be directly
obtained from clinical material, but it can be obtained
from experimental data. Therefore, experimental and
clinical data are complementary. The data from differ-
ent research groups have revealed that WNT5A expres-
sion in clinical breast cancer samples is marker of good
prognosis [8, 12, 14, 35], whereas CD44 expression has
been associated with poor prognosis [50]. Similar find-
ings have also been reported in triple-negative and basal
breast cancer tissues [13, 51]. Moreover, treatment with
either a WNT5A agonist [52] or a monoclonal antibody
against CD44 [53, 54] in mouse breast cancer models im-
paired tumor progression, which suggests a therapeutic
possibility. The present study demonstrated that WNT5A
signaling can suppress CD44 protein expression and
signaling, which supports the use of a WNT5A agonist in
the treatment of breast cancer patients.
Conclusions
Unlike in mammary epithelial cells, the inhibition of
migration and invasion by WNT5A signaling is an
EMT-independent event in breast cancer cells. This
study demonstrated that WNT5A inhibits CD44 expres-
sion and its downstream AKT signaling, which further
explains how WNT5A signaling impairs breast cancer
cell migration and invasion.
Additional files
Additional file 1: The loss of WNT5A in HB2 cells induces changes in
EMT markers and was restored by rWNT5A treatment. Semi-quantification
of a membranous E-cadherin and b Vimentin were performed using
ImgaeJ software, as described in the Methods section. For each experiment
between 10 and 15 cells were evaluated per slide. All error bars represent the
standard error of the mean. *p<0.05, **p=0.01, ***p=0.001. c HB2 cells were
transfected with WNT5A siRNA2 for 48 h followed by treatment with rWNT5A
(0.4 μg/ml) for 24 h. The cells were lysed, and Western blotting was performed
for the N-cadherin and Slug proteins. The quantification of d N-cadherin and
e Slug was performed by calculating the integrated densitometric values and
normalizing them to the tubulin levels. Statistical comparisons were made
with Student’s t-test (b and c). All error bars represent the standard error of
the mean (n=4). *p<0.05. (PDF 405 kb)
Additional file 2: The loss of E-cadherin alone can induce ‘EMT-like’
changes. HB2 cells were transiently transfected with E-cadherin siRNA for 48 h,
and changes in the cellular characteristics were investigated using a a transwell
invasion assay, b morphological analysis (20X magnification) and c Western
blotting. HB2 cells treated with scrambled siRNA served as a control. Statistical
comparisons were made with Student’s t-test (a). Error bars represent the
standard error of the mean (n=4). *p<0.05. (PDF 405 kb)
Additional file 3: WNT5A treatment has no effect on breast cancer cell
proliferation. Proliferation analysis was carried out using a BrdU incorporation
assay (as described in the Methods section). a MDA-MB468 and b MDA-
MB231 cells were treated with rWNT5A for 24, 48 and 72 h. Vehicle-treated
cells were used as controls. Statistical comparisons were made with Student’s
t-test (a and b). All error bars represent the standard error of the mean (n=3).
ns=non-significant. (PDF 405 kb)
Additional file 4: CD44 immunostaining in WNT5A-expressing breast
cancer cell lines. a MDA-MB468 and b MDA-MB-231 cells transfected with the
WNT5A plasmid (MDA-MB468-5A and MDA-MB231-5A) were allowed to grow
on 13-mm glass coverslips for 48 h and were then processed for CD44
immunofluorescence staining (as described in the Methods section). The
intensity of CD44 expression in WNT5A-expressing cancer cells was compared
with empty vector (EV)-transfected control cells (n=3). (PDF 405 kb)
Additional file 5: WNT5A mediated regulation of CD44 expression in
MDA-MB231 and HB2 mammary epithelial cells. a Representative western
blot showing the expression of CD44, pAKT and total AKT in MDA-MB231
cells treated with rWNT5A (0.2 and 0.4 μg/ml) for 24 h. b Human
mammary epithelial (HB2) cells were transfected with WNT5A siRNA2 for
48 h, followed by Western blotting for CD44 expression. CD44 was
quantified by calculating the integrated densitometric values and
normalizing them to the tubulin levels. Statistical comparisons were
made with Student’s t-test (b). All error bars represent the standard error
of the mean (n=3). *ns=non-significant. (PDF 404 kb)
Additional file 6: CD44 silencing significantly reduced the migration of
MDA-MB468 cells. MDA-MB468 cells were transiently transfected with
CD44 siRNA for 48 h (as described in the Methods section) and subjected
to transwell migration analysis. Statistical comparisons were made with
Student’s t-test. All error bars represent the standard error of the mean
(n=4). ***p=0.001. (PDF 405 kb)
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